Antiemetic Therapy for Nausea and Vomiting

Introduction to Antiemetic Options

The National Comprehensive Cancer Network recommends granisetron and palonosetron as the most effective 5-HT3 receptor antagonist alternatives to ondansetron, with granisetron available in oral, intravenous, and transdermal patch formulations 1, 2
Palonosetron has superior efficacy for delayed nausea compared to other 5-HT3 antagonists, and is available as an intravenous formulation 1, 3

Granisetron is effective for preventing nausea and vomiting, with a typical dosing of 2 mg daily, and can be administered via oral, intravenous, or transdermal patch formulations 1
Palonosetron is effective for preventing nausea and vomiting, with a typical dosing of 0.25 mg IV over 30 seconds, 30 minutes before chemotherapy, and has superior efficacy for delayed nausea compared to other 5-HT3 antagonists 1, 3
Dolasetron is available in oral form only, with a typical dosing of 100 mg, and IV dolasetron is no longer recommended due to increased risk of cardiac arrhythmias 1

Dexamethasone is highly effective when combined with 5-HT3 antagonists, with a typical dosing of 8-20 mg IV/oral for acute emesis, and is recommended by the National Comprehensive Cancer Network and the Annals of Oncology 2, 4
Methylprednisolone and prednisolone are alternative corticosteroid options, with typical dosing of 100 mg and 100-150 mg, respectively 2

Metoclopramide is effective for breakthrough emesis, with a typical dosing of 20-30 mg oral, 3-4 times daily, and is particularly useful for patients who have not responded to 5-HT3 antagonists 2, 5
Prochlorperazine and domperidone are alternative dopamine antagonist options, with typical dosing of 10-20 mg oral, 3-4 times daily, and 20 mg oral, 3-4 times daily, respectively 2

Aprepitant is effective for preventing nausea and vomiting, with a typical dosing of 125 mg on day 1, followed by 80 mg on days 2-3, and is particularly effective for highly emetogenic chemotherapy when combined with 5-HT3 antagonists and dexamethasone 1, 2

Lorazepam is effective for anticipatory nausea/vomiting, with a typical dosing of 1-2 mg oral, 1-4 times daily, and is particularly useful for patients who have not responded to other antiemetics 2, 5
Nabilone is FDA-approved for nausea and vomiting in patients who have not responded to conventional antiemetics, and is a useful option for refractory cases 5

For chemotherapy-induced nausea/vomiting, the National Comprehensive Cancer Network recommends palonosetron + dexamethasone + aprepitant for highly emetogenic chemotherapy, and granisetron or palonosetron, with or without dexamethasone, for moderately emetogenic chemotherapy 1, 3
For breakthrough emesis, adding an agent from a different class, such as a dopamine antagonist, is recommended 2, 5
For radiation-induced nausea/vomiting, granisetron with or without dexamethasone is recommended 5, 6
For anticipatory nausea/vomiting, lorazepam or alprazolam is recommended 5, 6
For refractory cases, combination therapy with multiple agents from different classes, and consideration of nabilone, is recommended 2, 5

Palonosetron has shown superior efficacy for both acute and delayed nausea compared to other 5-HT3 antagonists in meta-analyses, and is recommended by the National Comprehensive Cancer Network 1
Adding dexamethasone significantly improves antiemetic efficacy of all 5-HT3 antagonists, and is recommended by the National Comprehensive Cancer Network and the Annals of Oncology 1, 2
For elderly patients or those with liver disease, dose adjustments may be required, particularly for benzodiazepines, and is recommended by the National Comprehensive Cancer Network 5, 6
QT interval prolongation is a concern with high-dose ondansetron, but this is less of a concern with other 5-HT3 antagonists at standard doses, and is noted by the Praxis Medical Insights 4